Ablynx Initiates Phase II Clinical Trial For ALX-0081

Ablynx [Euronext Brussels: ABLX] announced the initiation of a Phase II study for its anti-thrombotic Nanobody® ALX-0081, a first-in-class Nanobody® targeting von Willebrand Factor (vWF). The open-label, randomized Phase II study is designed to evaluate the safety and efficacy of multiple doses of ALX-0081 versus the GPIIb/IIIa inhibitor ReoPro® in patients undergoing percutaneous coronary intervention (PCI).